Business Context and Reporting Period
Company: Bone Biologics Corp
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2015
Event: Entry into a material definitive agreement and unregistered sales of equity securities.
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial performance. The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics.
- Equity Issued: 915,614 shares of common stock.
- Warrants Issued: Warrants to purchase 158,229 shares of common stock.
- Warrant Exercise Price: $1.58 per share.
- Cash Payment: $275,000.
- Counterparty: AFH Holding & Advisory, LLC ("AFH").
- Purpose: Payment for advisory services rendered to the Company.
Material Changes and Related Party Information
The transaction involves a related party. Mr. Amir Heshmatpour is identified as the controlling party of AFH and serves as an affiliate and board observer of Bone Biologics Corp. The securities were issued in reliance on Section 4(2) of the Securities Act of 1933, exempting them from registration as they did not involve a public offering and were sold to sophisticated purchasers.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, or outlook. The primary risk disclosed relates to the issuance of unregistered securities and the concentration of advisory services with an affiliate.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the valuation of the advisory services provided by AFH relative to the $275,000 cash payment and equity issued.
- Review the terms of the warrants, including expiration dates and exercise conditions, which are not detailed in this summary.
- Assess the ongoing relationship and potential conflicts of interest with Mr. Amir Heshmatpour as a board observer and affiliate.